Introduction
Diabetes mellitus (DM) is a metabolic disorder characterized genetically, which can cause a variety of metabolic, neurologic, and vascular complications (1) . Although a correlation between DM and hearing loss has been show in numerous studies (2, 3) , there is still no consensus about the exact etiopathogenesis of hearing loss and the site of auditory system involvement (3) .
The medial olivocochlear (MOC) efferents originate from the medial part of the superior olivary complex on both sides, project through the vestibular nerve, and terminate on the outer hair cells of the cochlea (4) (5) (6) (7) . Stimulation of the MOC efferents results in an inhibition of outer hair cell activity in the cochlea and, in turn, a decrease in the amplitudes of otoacoustic emissions (OAEs) (8, 9) . The OAEs are generated by the outer hair cells in the cochlea, either spontaneously or in response to acoustic stimuli, and can be recorded in the external ear canal noninvasively. Thus, the combination of OAEs and contralateral acoustic stimulation (CAS) allows the investigation of the efferent cochlear innervations (4, 10, 11) . This effect is known as contralateral suppression (CLS) of OAEs and facilitates assessment of the MOC efferent system (4, 11, 12) .
The aim of the current study was to investigate the outer hair cell function and MOC efferent system by OAE tests in patients with type II DM.
Materials and methods
This research was performed in accordance with the principles of the Declaration of Helsinki, and approval for this study was granted by the local ethics committee. Written informed consents were obtained from the patients and controls tested in this study.
Patients and controls
There were 50 patients (100 ears) with type II DM who were diagnosed in the department of endocrinology and 51 healthy age-and sex-matched controls (102 ears) included in the study.
The mean age of patients with DM was 49.8 ± 5.1 years (range: 40-60 years). There were 34 (68%) female and 16 (32%) male patients. The mean age of the control group was 47.9 ± 4.8 years (range: 40-58 years), and there were 33 (64.7%) female and 18 (35.3%) male subjects. There was no significant difference between the ages and sexes of the patients and controls (P > 0.05).
None of the participants had a history of using ototoxic drugs, noise exposure, ear surgery, chronic middle ear disease, Meniere's disease, cranial trauma, metabolic diseases except for DM, otoscopic evidence of a perforated tympanic membrane or other middle ear pathology, presence of a flat tympanogram, or an air-bone gap of 5 dB or greater at any frequency.
In the patients, the mean duration of disease, glycosylated hemoglobin (HbA1c) levels, and simultaneous fasting glucose levels were recorded. In the control group, fasting glucose level was also recorded.
Audiometry and middle ear evaluation
The hearing examination included otoscopy, tympanometry, pure-tone audiometry, and speech audiometry. Pure-tone audiometry was performed at the frequencies of 250, 500, 1000, 2000, 4000, and 8000 Hz using a diagnostic audiometer (Madsen Orbiter 922-2 Clinical Audiometer, Copenhagen, Denmark) in a sound-treated cabin. Tympanometric measurements were done using a TDH-39 headset and middle ear analyzer (TympStar GSI, Grason-Stadler Inc., Milford, NH, USA). On tympanometry, all participants had a normal peak compliance, peak pressure, gradient and ear canal volume, and acoustic reflex, as defined by American Speech Language and Hearing Association.
OAE testing
All OAE measurements were performed bilaterally and were recorded using the ILO 292 USB II OAE analyzer, version 6 (Otodynamics Ltd., London, UK), with 2 ILO UGD TE+DPOAE probes (insert phone) in a sound-proof room.
DPOAE test parameters
Distortion product otoacoustic emission (DPOAE) testing was performed bilaterally using an ILO device. The emission at 2f1-f2 was the distortion product measured. Distortion product signal amplitude and noise floor across the range of frequencies corresponding to the following frequencies values for f2 were recorded: 1000, 1500, 2000, 3000, 4000, 5000, and 6000 Hz. The test parameters for DPOAEs were the following: stimulus, f1 = 65 dB, f2 = 55 dB, and 2f2/f1 = 1.22; time out (NLo), 500 sweeps or 100 s; noise rejection level, 49.5 dB sound pressure level (SPL); point/octave, 2.
Testing contralateral suppression of TEOAEs
The transient evoked otoacoustic emissions (TEOAEs) were registered on the linear click channel. The data set from the test with CAS was designated as memory store 1, and that from the test without CAS was designated as memory store 2. The CAS consisted of continuous broad band white noise at 60 dB SPL, delivered through channel B of the ILO and presented by ILO general purpose UGD TE+DPOAE probes. All subjects were tested bilaterally in a randomized fashion. After the 2 probes were in place, TEOAEs were recorded in alternating blocks (with and without CAS) for the linear mode, always in the same order. TEOAE contralateral suppression was calculated by subtracting the TEOAE level with CAS from the TEOAE level without CAS.
In
all patients, TEOAE with CAS [CAS (+)] and TEOAE without CAS [CAS (-)]
were recorded in linear mode, and test frequencies were at 1000, 1500,1000,3000, and 4000 Hz. Under all conditions, the intensity of the clicks was 80 dB SPL, and a total of 260 sweeps were recorded for each ear. The measurements were averaged after 260 responses and were only accepted when stimulus stability was better than 80%. The linear TEOAE recording mode is the most sensitive at CLS.
Statistical analyses
The statistical analyses were performed using SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). A chi-square test was used to compare the DM and control groups regarding sex and the rate of hearing loss. The independent sample t-test was used to compare the ages and all audiological parameters of the patients and controls. Pearson correlation and linear regression analysis were used in correlation analyses of TEOAE, DPOAE, and TEOAE with and without CAS with mean duration of disease and HbA1c blood levels. P < 0.05 (2-tailed) was regarded as statistically significant.
Results
The mean duration of diabetes mellitus was 8.1 ± 5.8 years (range: 1-20 years). The mean blood level of HbA1c was 8.1 ± 2.27 (5.22-13.12) and of glucose was 171.6 ± 73.6 (75-340) mg/dL in the patient group. HbA1c was within the normal range only in 6% of the diabetic patients. The mean blood level of glucose was 92.9 ± 8.5 (66-110) mg/ dL in the control group. There was a significant difference between the mean blood glucose levels of the patients and controls (P < 0.0001, independent sample t-test). Twentyeight percent of the diabetic patients were taking insulin in the management of their disease. The rest were taking oral antidiabetic medications or attempting to control their diabetes by diet.
As there was no air-bone gap in the participants, only air conduction thresholds were taken into consideration. Since there was no difference between the right and left ears of both groups, the results of both ears were taken into consideration in the statistical analyses. The pure-tone audiometric thresholds of the groups are shown in Table  1 . There was a significant difference between the pure-tone thresholds of the patients and controls at all frequencies (P < 0.05, independent sample t-test).
The mean speech discrimination scores of the patient and control groups were 94.1 ± 6.6% (range: 68%-100%) and 96.5 ± 4.7% (range: 72%-100%), respectively (P = 0.004, independent sample t-test). The pure-tone average (PTA) of air conduction thresholds at 500, 1000, and 2000 Hz was measured separately for each ear. Hearing loss was defined as a pure-tone threshold level higher than 15 dB at any test frequency (11) . The rates of hearing loss at each test frequency of the groups are shown in the Figure. There was a significant difference between the rate of sensorineural hearing loss (SNHL) of the patients and controls at all test frequencies (0.05, chi-square test).
The DPOAEs, noise floor, and signal-to-noise ratio (SNR) findings of the patients and controls are shown in Table 2 . There were statistically significant differences between the levels of SNR of the patients and controls at all frequencies (P < 0.05) except for the 1000 Hz results on DPOAE testing. The CAS (-) and CAS (+) TEOAE findings of the patients and controls are shown in Tables  3 and 4 . There was no statistically significant difference between CLS test results of patients and controls (P > 0.05). In our study, no correlation was found between CAS (-) and CAS (+) SNR amplitudes at specific frequencies and disease duration, glucose blood level, or HbA1c and test parameters. 
Discussion
In our study we evaluated the auditory functions not only traditionally but also by detailed audiological tests. According to our audiometric test results, there was SNHL in the diabetic patients at all test frequencies. We found a statistically significant difference between the SNR levels of the patients and controls at all frequencies except for 1000 Hz on DPOAE testing. We also found that there was no significant difference between CLS amplitudes of the patients and controls. This means that the MOC system is not affected by type II DM. In the literature, different types of hearing losses were reported in diabetic patients, such as bilateral SNHL, affecting hearing at high frequencies.
In our study, there was SNHL that affected hearing at high frequencies in both patients and controls. This may result from presbycusis; however, hearing loss in the patients was more severe than in the controls. Although some studies reported that DM is one of the possible reasons for sudden SNHL, this had happened in none of our patients.
In our study, hearing thresholds of males at 4000 and 8000 Hz were higher than those of females in both patients and controls, and there was no correlation between hearing loss and age. Cullen and Cinnamond reported that hearing loss is more prominent in male diabetics than female diabetics, which is possibly due to males being exposed to environmental noise more frequently than females (14) . Age is another factor leading to hearing loss, and the presence of DM accelerates age-related hearing loss, or presbycusis, by synergistic action (14) . In our study the relationship between disease duration and hearing loss is a matter of controversy. Ottaviani et al. (16) did not find a correlation among the disease duration, HbA1c, OAE amplitudes, and neuropathy in their regression analysis model.
In our study we found that there was a statistically significant difference between the levels of SNR of the patients and controls at all frequencies except for 1000 Hz on DPOAE testing. This study confirms that cochlear function is affected at all frequency regions in DM patients. Measurement of DPOAEs corresponds closely SNR: signal-to-noise ratio; SPL: sound pressure level; Min. = minimum; Max. = maximum; SD = standard deviation.
to the physiological state of the outer hair cells of the cochlea (16) . DPOAEs are mainly used in the assessment of cochlear function to determine the site of pathology associated with SNHL. DPOAEs, if normal, provide extremely strong evidence of normal cochlear function, regardless of the audiometric data (17). We did not find any significant difference between CLS amplitudes of the patients and controls. Namyslowski et al. (19) and Ugur et al. (20) reported that there was a significant decrease in the TEOAE suppression amplitudes in children with DM. The lack or reduction of CLS amplitude is a pathologic state implicating auditory neuropathy or dyssynchrony (20) . The cochlea is innervated by the olivocochlear efferent system, and the thick and myelinated MOC efferent fibers originate from the medial part of the superior olivary complex on both sides (20) and project through the inferior vestibular nerve (4, 21, 22) .
In our study the patients and controls were middleaged, between 40 and 60 years old. Many studies confirmed that the suppression effect on the MOC system decreases with age, and auditory pathway structures begin to degenerate at 40 years of age (23, 24) . This may explain our results with the decrease of olivocochlear system function. The preference of stimulus is important in OAE test procedures because the appropriate stimulus can provide better results, especially in some specific measurements. Linear stimulation is more sensitive in detecting shifts in the TEOAEs recorded in the presence of competitive noise than in those recorded without competitive environmental noise (25, 26) . However, it has some technical limitations, and therefore some authors recommend using the nonlinear mode of stimulation in detecting CLS of TEOAEs in clinical settings (18) (19) (20) . In our study, we used the linear stimulus mode, which was more sensitive. In the literature, although several clinical and experimental studies exist about evaluation of the MOC function in patients with type I DM (18, 19, 27) , we did not find any clinical study performed in patients with type II DM, and the current study is the first of this topic.
Makashima and Tanaka described atrophy of spiral ganglion neurons and demyelination of the eighth cranial nerve in 4 DM subjects. Histopathological studies of the inner ear in the patients with DM showed a thickening in the walls of capillaries in the stria vascularis and degeneration in the organ of Corti and outer hair cells (28) . Additionally, abnormal auditory brainstem response results can also suggest impairment in the central neural conduction process of the auditory system in DM (28, 29) .
In conclusion, audiological results suggest that type II DM seems to have an important impact on outer hair cells in the auditory system. The audiometric thresholds at all test frequencies increased, and except for at 1000 Hz, the amplitudes of DPOAEs at all frequencies decreased in diabetic patients. Our results suggest that an impairment of the outer hair cells is evident in the cochlea. The MOC efferent system was not affected in type II diabetic patients.
